Clinical Trial Update: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating visilizumab for intravenous steroid-refractory ulcerative colitis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Visilizumab (visilizumab)

Snippet

Sponsor: Facet Biotech | Conditions: Intravenous Steroid-Refractory Ulcerative Colitis | Phase 3 | Status: WITHDRAWN